Stocks · News reference
NeoGenomics’ RaDaR ST Molecular Residual Disease Assay Receives Expanded Coverage From CMS’ MolDX To Include Immunotherapy Monitoring For Patients With Late-Stage Solid Tumors
New coverage extends RaDaR ST to patients with advanced cancer on immunotherapy, expanding MRD testing across the cancer care continuumNeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 26, 2026, 8:20 PM
- Checked
- Aug 26, 2026, 8:20 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Greenland Mines Outlines $2B Valuation for Sarfartoq Project
Greenland Mines released an Initial Assessment for its Sarfartoq project, projecting a pre-tax net present value up to $2.05 billion.
Read original at benzingaNeoGenomics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
Read original at benzinga